Assessing response and loss of response to biological therapies in IBD

American Journal of Gastroenterology

Volumn 106, Issue 4, 2011, Pages 685-698

  Yanai, Henit ^a   Hanauer, Stephen B ^b  

^a TEL AVIV UNIVERSITY   (Israel)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CERTOLIZUMAB PEGOL; DRUG ANTIBODY; INFLIXIMAB; NATALIZUMAB; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANTIBODY RESPONSE; APOPTOSIS; BINDING AFFINITY; BIOLOGICAL THERAPY; CENTRAL NERVOUS SYSTEM INFECTION; CLINICAL ASSESSMENT TOOL; CLINICAL DECISION MAKING; CROHN DISEASE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG MONITORING; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECZEMA; HEALING; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RASH; REVIEW; SKIN DEFECT; SKIN MANIFESTATION; T LYMPHOCYTE; TREATMENT FAILURE; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADULT; ANTIBODY FORMATION; BIOLOGICAL THERAPY; COLITIS; CROHN DISEASE; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; ILEITIS; INFLAMMATORY BOWEL DISEASES; MALE; RETREATMENT; RISK ASSESSMENT; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79953788656     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2011.103     Document Type: Review

References (101)

1. Bamias G, Nyce MR De La Rue SA et al New concepts in the pathophysi-ology of Infammatory bowel disease. Ann Intern Med 2005; 143: 895-904. (Pubitemid 46202223)
2. Baumgart D C, Carding SR Infammatory bowel disease: cause and immunobiology Lancet 2007;369:1627-40.
3. Cho JH, Weaver CT. Te genetics of infammatory bowel disease. Gastroenterology 2007;133:1327-39.
4. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of Infammatory bowel disease. Nature 2007;448:427-34. (Pubitemid 47123518)
5. Wong M, Ziring D, Korin Y et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol 2008;126:121-36.
6. Braegger CP, Nicholls S, Murch SH et al Tumour necrosis factor alpha in stool as a marker of intestinal infammation. Lancet 1992;339:89-91.
7. MacDonald TT, Hutchings P, Choy MY et al. Tumour necrosis factor-alpha and interferon-gamma production measured at the single cell level in normal and infamed human intestine. Clin Exp Immunol 1990;81:301-5. (Pubitemid 20242538)
8. Schreiber S, Nikolaus S, Hampe J et al. Tumour necrosis factor alpha and interleukin 1beta in relapse of Crohn's disease. Lancet 1999;353:459-61. (Pubitemid 29067338)
9. Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance inf iximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9. (Pubitemid 34621118)
10. Sands BE, Anderson FH, Bernstein CN et al. Inf iximab maintenance therapy for fstulizing Crohn's disease. N Engl J Med 2004;350:876-85. (Pubitemid 38252535)
11. Targan SR, Hanauer SB, van Deventer SJ et al A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997;337:1029-35.
12. Clark M, Colombel JF, Feagan BC et al American gastroenterological association consensus development conference on the use of biologics in the treatment of infammatorybowel disease, June 21-23, 2006. Gastroenterology 2007;133:312-39. (Pubitemid 47031141)
13. Lichtenstein GR, Bala M, Han C et al Inf iximab improves quality of life in patients with Crohn's disease. Infamm Bowel Dis 2002;8:237-43. (Pubitemid 34784975)
14. Colombel JF, Sandborn WJ, Rutgeerts P et al Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65. (Pubitemid 46108762)
15. Colombel JF, Schwartz DA, Sandborn WJ et al Adalimumab for the treat-ment of f stulas in patients with Crohn's disease. Gut 2009; 58: 940-8.
16. Hanauer SB, Sandborn WJ, Rutgeerts P et al Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33; quiz 591.
17. Lichtenstein GR, Tomsen OO, Schreiber S et al Continuous therapy with certolizumab pegol maintains remission of patients with Crohn's disease for up to 18 months. Clin Gastroenterol Hepatol 2010; 8: 600-9.
18. Sandborn WJ, Feagan BG, Stoinov S et al Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007;357:228-38. (Pubitemid 47080387)
19. Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007;56: 1232-9. (Pubitemid 47300424)
20. Sandborn WJ, Rutgeerts P, Enns R et al Adalimumab induction therapy for Crohn disease previously treated with inf iximab: a randomized trial. Ann Intern Med 2007;146:829-38. (Pubitemid 351650483)
21. Schreiber S, Khaliq-Kareemi M, Lawrance IC et al Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007;357:239-50. (Pubitemid 47080388)
22. Schreiber S, Rutgeerts P, Fedorak RN et al A randomized, placebo-control-led trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005;129:807-18. (Pubitemid 41242673)
23. Sandborn WJ, Hanauer SB, Katz S et al Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001;121:1088-94. (Pubitemid 33022088)
24. Wolbink GJ, Aarden LA, Dijkmans BA. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 2009;21:211-5.
25. Maser EA, Villela R, Silverberg MS et al Association of trough serum infiximab to clinical outcome af er scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1248-54. (Pubitemid 44512213)
26. Baert F, Noman M, Vermeire S et al Inf uence of immunogenicity on the long-term ef cacy of inf iximab in Crohn's disease. N Engl J Med 2003;348:601-8. (Pubitemid 36204954)
27. West RL, Zelinkova Z, Wolbink GJ et al Immunogenicity negatively inf uences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ter 2008;28:1122-6.
28. Fidder H, Schnitzler F, Ferrante M et al Long-term safety of inf iximab for the treatment of Infammatory bowel disease: a single-centre cohort study Gut 2009;58:501-8.
29. Lichtenstein GR, Feagan BG, Cohen RD et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry Clin Gastroenterol Hepatol 2006; 4: 621-30.
30. Toruner M, Lofus EV Jr, Harmsen WS et al Risk factors for opportunistic infections in patients with Infammatory bowel disease. Gastroenterology 2008;134:929-36. (Pubitemid 351451967)
31. Siegel CA, Marden SM, Persing SM et al Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009;7:874-81.
32. Mackey AC, Green L, Liang LC et al Hepatosplenic T cell lymphoma associated with inf iximab use in young patients treated for Infammatory bowel disease. J Pediatr Gastroenterol Nutr 2007;44:265-7. (Pubitemid 46175082)
33. Shale M, Kanfer E, Panaccione R et al Hepatosplenic T cell lymphoma in Infammatory bowel disease. Gut 2008; 57: 1639-41.
34. Rutgeerts P, Sandborn WJ, Feagan BG et al Inf iximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462-76. (Pubitemid 41770166)
35. Ghosh S. Terapeutic value of alpha-4 integrin blockade in Infammatory bowel disease: the role of natalizumab. Expert Opin Biol Ter 2003;3: 995-1000. (Pubitemid 37093154)
36. Ghosh S, Goldin E, Gordon FH et al Natalizumab for active Crohn's disease. N Engl J Med 2003;348:24-32. (Pubitemid 36026343)
37. Yousry TA, Major EO, Ryschkewitsch C et al Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy N Engl J Med 2006;354:924-33.
38. Vermeire S, van Assche G, Rutgeerts P. Review article: altering the natural history of Crohn's disease\evidence for and against current therapies. Aliment Pharmacol Ter 2007;25:3-12. (Pubitemid 44902859)
39. D'Haens GR Fedorak R, Lemann M et al Endpoints for clinical trials evaluating disease modif cation and structural damage in adults with Crohn's disease. Infamm Bowel Dis 2009;15:1599-604.
40. Bendtzen K, Geborek P Svenson M et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor inf iximab. Arthritis Rheum 2006;54:3782-9. (Pubitemid 44955878)
41. Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-inf iximab antibodies measured by f uid-phase radioimmunoassays as predictors of clinical ef cacy of inf iximab in Crohn's disease. Am J Gastroenterol 2008; 103: 944-8. (Pubitemid 351501078)
42. Teber Te C, Das KM, Mehta V et al Non-response to inf iximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies. Clin Exp Immunol 2008;154:325-31.
43. Cosnes J, Cattan S, Blain A et al Long-term evolution of disease behavior of Crohn's disease. Infamm Bowel Dis 2002;8:244-50. (Pubitemid 34784976)
44. Lionetti P, Bronzini F, Salvestrini C et al Response to inf iximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ter 2003;18:425-31. (Pubitemid 37070241)
45. Kugathasan S, Werlin SL, Martinez A et al Prolonged duration of response to inf iximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000;95:3189-94.
46. Hyams J, CrandallW, Kugathasan S et al Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863-73; quiz 1165-6. (Pubitemid 46454266)
47. Louis EJ, Watier HE, Schreiber S et al Polymorphism in IgG Fc receptor gene FCGR3A and response to inf iximab in Crohn's disease: a subanalysis of the ACCENT I study Pharmacogenet Genomics 2006; 16: 911-4. (Pubitemid 44772809)
48. Louis E, El Ghoul Z, Vermeire S et al Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to inf iximab in Crohn's disease. Aliment Pharmacol Ter 2004;19:511-9. (Pubitemid 38387177)
49. Arijs I, Li K, Toedter G et al Mucosal gene signatures to predict response to inf iximab in patients with ulcerative colitis. Gut 2009; 58: 1612-9.
50. Hlavaty T, Pierik M, Henckaerts L et al Polymorphisms in apoptosis genes predict response to inf iximab therapy in luminal and f stulizing Crohn's disease. Aliment Pharmacol Ter 2005;22:613-26. (Pubitemid 41415989)
51. Bartelds GM, Wijbrandts CA, Nurmohamed MTet al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921-6. (Pubitemid 46999794)
52. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93: 2645-68. (Pubitemid 39506617)
53. Farrell RJ, Alsahli M, Jeen YTet al Intravenous hydrocortisone premedi-cation reduces antibodies to inf iximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-24. (Pubitemid 36389794)
54. Vermeire S, Noman M, Van Assche G et al effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infiximab in Crohn's disease. Gut 2007;56:1226-31. (Pubitemid 47300423)
55. Hanauer SB, Wagner CL, Bala M et al Incidence and importance of anti-body responses to inf iximab af er maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004;2:542-53. (Pubitemid 38834038)
56. Bendtzen K, Ainsworth M, Steenholdt C et al Individual medicine in Infammatory bowel disease: monitoring bioavailability pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol 2009;44:1-8.
57. Svenson M, Geborek P Saxne Tet al Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum inf iximab and anti-infiximab antibodies. Rheumatology (Oxford) 2007;46:1828-34. (Pubitemid 350168300)
58. Knight DM, Trinh H, Le J et al Construction and initial characterization of a mouse-human chimeric anti-TNF antibody Mol Immunol 1993; 30:1443-53.
59. St Clair EW, Wagner CL, Fasanmade AA et al Te relationship of serum inf iximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1451-9. (Pubitemid 34620190)
60. Mulleman D, Chu Miow Lin D, Ducourau E et al Trough inf iximab concentrations predicTef cacy and sustained control of disease activity in rheumatoid arthritis. Ter Drug Monit 2010;32:232-6.
61. Mori S. A relationship between pharmacokinetics (PK) and the ef cacy of inf iximab for patients with rheumatoid arthritis: characterization of inf iximab-resistant cases and PK-based modif ed therapy. Mod Rheumatol 2007;17:83-91. (Pubitemid 46614350)
62. Wolbink GJ, Voskuyl AE, Lems WF et al Relationship between serum trough inf iximab levels, pretreatment C reactive protein levels, and clinical response to inf iximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:704-7. (Pubitemid 40559296)
63. Seow CH, Newman A, Irwin SP et al. Trough serum inf iximab: a predic-tive factor of clinical outcome for inf iximab treatment in acute ulcerative colitis. Gut 2010;59:49-54.
64. Li J, Paulson S, Chiu Y et al Evaluation ofpotential correlations between serum adalimumab concentration and remission in patients with Crohn's disease in classic I and II. Gastroenterology 2010; 138: 741.
65. Karmiris K, Paintaud G, Noman M et al Inf uence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009;137:1628-40.
66. Radstake TR, Svenson M, Eijsbouts AM et al. Formation of antibodies against inf iximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009;68:1739-45.
67. Rutgeerts P, Feagan BG, Lichtenstein GR et al Comparison of scheduled and episodic treatment strategies of inf iximab in Crohn's disease. Gastroenterology 2004;126:402-13. (Pubitemid 38182297)
68. Schnitzler F, Fidder H, Ferrante M et al. Long-term outcome of treatment with inf iximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009;58:492-500.
69. Furst DE, Schif MH, Fleischmann RM et al Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003 30: 2563-71. (Pubitemid 37549331)
70. Keystone EC, Kavanaugh AF, Sharp JTet al Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11. (Pubitemid 38608061)
71. Lipsky PE, van der Heijde DM, St Clair EW et al Inf iximab and meth-otrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Terapy Study Group. N Engl J Med 2000;343:1594-602.
72. Maini R St Clair EW, Breedveld F et al Inf iximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999;354:1932-9.
73. Weinblatt ME, Keystone EC, Furst DE et al Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial Arthritis Rheum 2003. 48. 35-45. (Pubitemid 36091645)
74. Weisman MH, Moreland LW, Furst DE et al Effcacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study Clin Ter 2003;25: 1700-21. (Pubitemid 36801943)
75. Sandborn WJ, Colombel JF, Enns R et al Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005;353: 1912-25. (Pubitemid 41565956)
76. Van Assche G, Magdelaine-Beuzelin C, D ' Haens G et al Withdrawal of immunosuppression in Crohn's disease treated with scheduled inf iximab maintenance: a randomized trial. Gastroenterology 2008;134:1861-8. (Pubitemid 351790744)
77. Sandborn WJ, Rutgeerts PJ, Reinisch W et al 751f one year data from the sonic study: a randomized, double-blind trial comparing inf iximab and inf iximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy Gastro enterology 2009;136:A-116.
78. van der Bijl AE, Breedveld FC, Antoni CE et al An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous inf iximab treatment: relationship to reasons for failure and anti-infiximab antibody status. Clin Rheumatol 2008;27:1021-8.
79. Seiderer J, Brand S, Dambacher J et al Adalimumab in patients with Crohn's disease\safety and Effcacy in an open-label single centre study Aliment Pharmacol Ter 2007;25:787-96. (Pubitemid 46434910)
80. Ho GT, Smith L, Aitken S et al Te use of adalimumab in the management of refractory Crohn's disease. Aliment Pharmacol Ter 2008;27:308-15.
81. Danese S,Mocciaro F, GuidiLet al. Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to inf iximab: a real-life multicenter experience of compassionate use. Infamm Bowel Dis 2008;14:1168-70.
82. Rubbert-Roth A, Finckh A. Treatment options in patients with rheu-matoid arthritis failing initial TNF inhibitor therapy: a critical review Arthritis Res Ter 2009;11 (Suppl1): S1.
83. Targan SR, Feagan BG, Fedorak RN et al Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007;132:1672-83. (Pubitemid 46695722)
84. Aff W, Lofus EV Jr, Faubion WA et al Clinical utility of measuring inf iximab and human anti-chimeric antibody concentrations in patients with infammatorybowel disease. Am J Gastroenterol 2010;105:1133-9.
85. Kaplan GG, Hur C, Korzenik J et al Inf iximab dose escalation vs. initiation of adalimumab for loss of response in Crohn's disease: a cost-effectiveness analysis. Aliment Pharmacol Ter 2007;26:1509-20. (Pubitemid 350178810)
86. Sandborn WJ, Hanauer SB, Rutgeerts PJ et al Re-induction and maintenance therapy with subcutaneous certolizumab pegol in patients with Crohn's disease following treatment failure: PRECiSE 4 results. Gastroenterology 2007;132:A505.
87. Fiorino G, Allez M, Malesci A et al Review article: anti TNF-alpha induced psoriasis in patients with infammatory bowel disease. Aliment Pharmacol Ter 2009;29:921-7.
88. Haraoui B, Krelenbaum M. Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agenTetanercept for ankylosing spondyli-tis: possible mechanisms of action. Semin Arthritis Rheum 2009; 39: 176-81.
89. Cohen SB, Emery P Greenwald MW et al Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary Effcacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806. (Pubitemid 44497758)
90. Genovese MC, Becker JC, Schif M et al Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005;353:1114-23. (Pubitemid 41317434)
91. Finckh A, Ciurea A, Brulhart L et al B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 2007;56:1417-23. (Pubitemid 46764068)
92. Finckh A, Ciurea A, Brulhart L et al. Which subgroup of rheumatoid arthritis patients benef ts from switching to rituximab versus alternative anti-TNF agents afer previous failure to anti-TNF agent? Ann Rheum Dis 2010;69:387-93.
93. Sandborn WJ, Hanauer S, Lofus EV Jr et al An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to inf iximab for Crohn's disease. Am J Gastroenterol 2004;99:1984-9. (Pubitemid 39421244)
94. Vermeire S, Abreu MT, D'Haens G et al. Effcacy and safety of certolizu-mab pegol in patients with active Crohn's disease who previously lost response or were intolerant to inf iximab: open-label induction preliminary results of the WELCOME study. Gastroenterology 2008;134: A-67-8.
95. Panaccione R, Sandborn WJ, D'Haens G et al 920 Adalimumab maintains long-term remission in moderately to severely active Crohn's disease af er inf iximab failure: 1-year follow-up of gain trial. Gastroenterology 2008;134:A-133-4.
96. Oussalah A, Babouri A, Chevaux JB et al Adalimumab for Crohn's disease with intolerance or lost response to inf iximab: a 3-year single-centre experience. Aliment Pharmacol Ter 2009;29:416-23.
97. Lichtiger S, Present DH, Wu E et al T1061 Improvement in short inf am-matory bowel disease questionnaire scores in adalimumab-treated Crohn's disease patients who failed infiximab (CHOICE trial). Gastroenterology 2008;134:A-474-5.
98. Allez M, Vermeire S, Mozziconacci N et al Te Effcacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease af er failure of two other anti-TNF antibodies. Aliment Pharmacol Ter 2010;31:92-101.
99. Lashner B, Colombel JF, Enns R et al Natalizumab induces sustained response and remission in the absence of concomitant immunosuppres-sants in patients with crohn's disease who failed prior anti-TNF α therapy Am J Gastroenterol 2007;102 (Suppl2): S493.
100. Reinisch W Sandborn WJ, Hommes DW et al Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011.
101. Teisner AS, Ainsworth MA, Brynskov J. Long-term Effects and colectomy rates in ulcerative colitis patients treated with inf iximab: a Danish single center experience. Scand J Gastroenterol 2010;45:1457-63.